All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @moremayamoore on TikTok · 130s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @moremayamoore's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00one that we're hearing more and more about all the time,
  2. 0:03and that's BPC-157.
  3. 0:05Body protection compound 157.
  4. 0:08But a lot of people now taking VPC in various forms.
  5. 0:11Yeah.
  6. 0:13What are some known uses for VPC?
  7. 0:16Let's just say within your clinic.
  8. 0:18So many.
  9. 0:19So I think with VPC, for me,
  10. 0:21kind of the most utilized peptide that we've used.
  11. 0:24So we'd like to use VPC almost with every patient.
  12. 0:28It is very anti-inflammatory.
  13. 0:30And so just from a very general perspective,
  14. 0:33most people walking around who are adults,
  15. 0:36they're stiff, they're sore as they get older,
  16. 0:38they work out, work with athletes of all levels.
  17. 0:41There's that element of inflammation.
  18. 0:43Maybe they have some chronic disease,
  19. 0:45diabetes, heart disease, autoimmune disease.
  20. 0:47Inflammation is paramount, we understand that.
  21. 0:49And BPC, I observe with so many patients,
  22. 0:53we're talking thousands, thousands of patients,
  23. 0:55but their inflammation comes down.
  24. 0:57So they feel better.
  25. 0:58They're not as stiff, they're not as sore.
  26. 0:59Their knee doesn't hurt as much.
  27. 1:00Their shoulders improve.
  28. 1:02You name it, honestly, almost everyone I could think of,
  29. 1:05particularly as people are engaging more fitness-related lives,
  30. 1:08they're working out more.
  31. 1:09I would argue that anyone who's working out
  32. 1:11on a regular basis, VPC is gonna benefit.
  33. 1:14VPC 157, strongly anti-inflammatory.
  34. 1:16Yes.
  35. 1:17My understanding is it also may
  36. 1:18upregulate growth hormone research.
  37. 1:19It's a good size, right?
  38. 1:20And so it works well if you're, you know,
  39. 1:23we'll get into taking a growth hormone release and peptide.
  40. 1:25It pairs very well with that.
  41. 1:27Because then you're working both sides of the equation,
  42. 1:28meaning if you're using a growth hormone releasing peptide
  43. 1:31like semarone or epimerone, GHRP-6, whatever,
  44. 1:34you're helping your pituitary put out more growth hormone.
  45. 1:37Well, if you combine it with BPC,
  46. 1:38which upregulates the growth hormone receptor,
  47. 1:40you make the process of growth hormone
  48. 1:42and finding more efficient.
  49. 1:44So you get more out of it.
  50. 1:45Then you can use less of the growth hormone releasing peptide
  51. 1:48with the same result.
  52. 1:49Got it.
  53. 1:50Yeah. At some point, I think in the meantime, however,
  54. 1:54I think there's a lot of interest in BPC-157,
  55. 1:57a lot of use of BPC-157.
  56. 2:00The sources of BPC-157 are now drying up.
  57. 2:03Yeah.
  58. 2:03And that's why I'm personally concerned
  59. 2:06that people are going to start going
  60. 2:07to the dark gray market and black market.

@moremayamoore's peptide therapy claims need scrutiny

Maya Moore

TikTok creator

45.3K viewsWatch on TikTok →

Quick answer

The creator presents BPC-157 as a broadly beneficial anti-inflammatory peptide appropriate for nearly all patients, particularly those who are physically active, and recommends stacking it with growth hormone-releasing peptides like ipamorelin or GHRP-6 to amplify GH axis signaling. While preclinical evidence supports anti-inflammatory and tissue-repair mechanisms, no published human RCTs exist to support these clinical recommendations, and the FDA has restricted BPC-157 from use in compounded formulations as of 2023. Patients should understand that a clinician's anecdotal experience with thousands of patients does not replace controlled trial evidence, and that sourcing and purity risks are substantial given current regulatory constraints.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion
Start provider reviewBrowse video library

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @moremayamoore's peptide therapy claims need scrutiny, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

ReviewBPC-157 evidence2025

Multifunctionality and Possible Medical Application of the BPC 157 Peptide

Used to frame BPC-157 as an investigational peptide with mixed preclinical and limited human evidence.

PubMed

ReviewBPC-157 evidence2019

Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing

Supports cautious tissue-repair context without presenting BPC-157 as an approved therapy.

PubMed

ReviewGrowth-hormone peptide evidence1998

Ipamorelin, the first selective growth hormone secretagogue

Background source for ipamorelin selectivity and GH-secretagogue mechanism.

PubMed

ReviewGrowth-hormone peptide evidence2001

The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation

Preclinical context that should not be overstated as consumer clinical evidence.

PubMed

Provider decision path

Use local research to choose a safer review path

Direct answer

@moremayamoore's peptide therapy claims need scrutiny is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Start the provider review

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Helpful context before the funnel

Review method

See how FormBlends checks viral health claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@moremayamoore's peptide therapy claims need scrutiny" from Maya Moore. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator presents BPC-157 as a broadly beneficial anti-inflammatory peptide appropriate for nearly all patients, particularly those who are physically active, and recommends stacking it with growth hormone-releasing peptides like ipamorelin or GHRP-6 to amplify GH axis signaling.

The reason this review is not generic is the source wording and the canonical claim label "peptides tiktok 7475493468425456938." In this clip, the useful excerpt is: "one that we're hearing more and more about all the time, and that's BPC-157." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Multifunctionality and Possible Medical Application of the BPC 157 Peptide (2025), Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing (2019), and Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The FDA restricted BPC-157 from compounding pharmacy use in 2023, meaning most current access is through unregulated research chemical suppliers with no quality guarantees.
People who land here are usually trying to understand whether the Peptide social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator presents BPC-157 as a broadly beneficial anti-inflammatory peptide appropriate for nearly all patients, particularly those who are physically active, and recommends stacking it with growth hormone-releasing peptides like ipamorelin or GHRP-6 to amplify GH axis signaling.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator presents BPC-157 as a broadly beneficial anti-inflammatory peptide appropriate for nearly all patients, particularly those who are physically active, and recommends stacking it with growth hormone-releasing peptides like ipamorelin or GHRP-6 to amplify GH axis signaling. While preclinical evidence supports anti-inflammatory and tissue-repair mechanisms, no published human RCTs exist to support these clinical recommendations, and the FDA has restricted BPC-157 from use in compounded formulations as of 2023. Patients should understand that a clinician's anecdotal experience with thousands of patients does not replace controlled trial evidence, and that sourcing and purity risks are substantial given current regulatory constraints.
  • BPC-157 has no published human RCTs supporting its use for inflammation, joint pain, or musculoskeletal recovery as of 2024. All efficacy data is from animal models.
  • The FDA restricted BPC-157 from compounding pharmacy use in 2023, meaning most current access is through unregulated research chemical suppliers with no quality guarantees.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • BPC-157 has no published human RCTs supporting its use for inflammation, joint pain, or musculoskeletal recovery as of 2024. All efficacy data is from animal models.
  • The FDA restricted BPC-157 from compounding pharmacy use in 2023, meaning most current access is through unregulated research chemical suppliers with no quality guarantees.
  • Sikiric et al. (2018, Current Pharmaceutical Design) documented consistent anti-inflammatory and tissue-healing effects in rodents, which is the legitimate preclinical basis for clinical interest.
  • The claim that stacking BPC-157 with ipamorelin or GHRP-6 creates synergistic GH benefits in humans is speculative. No human trial has tested this combination.
  • Cohen et al. (2022, JAMA Internal Medicine) documented contamination, incorrect concentrations, and mislabeled compounds in unregulated peptide markets, which is the real risk of gray-market sourcing.
  • Anecdotal outcomes from a clinical practice, even at scale, cannot establish that BPC-157 works better than placebo without a control group. This is how confirmation bias enters clinical decision-making.
  • If a provider recommends BPC-157 without disclosing its unproven status in humans and the current regulatory constraints, ask specifically which human studies support the recommendation.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @moremayamoore actually say?

The creator, appearing to be a clinician, made several sweeping claims about BPC-157 (referred to throughout as "VPC" due to what sounds like a mic or speech issue). The core argument: BPC-157 is "very anti-inflammatory," benefits "anyone who's working out on a regular basis," and may upregulate growth hormone receptors, making it a useful pairing with growth hormone-releasing peptides like ipamorelin or GHRP-6. The creator also flagged a supply concern, warning that sources are "drying up" and people may turn to "the dark gray market and black market."

These are not fringe claims. BPC-157 has a genuine research footprint, and the creator isn't entirely wrong. But the gap between what animal studies show and what we can claim about human outcomes is enormous, and that gap got glossed over here. The "thousands of patients" framing is doing a lot of heavy lifting in place of actual clinical evidence.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Maya Moore · TikTok creator

45.3K views on this video

@moremayamoore's peptide therapy claims need scrutiny

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about bpc-157 has no published human rcts supporting its use for?

BPC-157 has no published human RCTs supporting its use for inflammation, joint pain, or musculoskeletal recovery as of 2024. All efficacy data is from animal models.

What does the video say about the fda restricted bpc-157 from compounding pharmacy use in 2023,?

The FDA restricted BPC-157 from compounding pharmacy use in 2023, meaning most current access is through unregulated research chemical suppliers with no quality guarantees.

What does the video say about sikiric et al. (2018, current pharmaceutical design) documented consistent anti-inflammatory?

Sikiric et al. (2018, Current Pharmaceutical Design) documented consistent anti-inflammatory and tissue-healing effects in rodents, which is the legitimate preclinical basis for clinical interest.

What does the video say about the claim?

The claim that stacking BPC-157 with ipamorelin or GHRP-6 creates synergistic GH benefits in humans is speculative. No human trial has tested this combination.

What does the video say about cohen et al. (2022, jama internal medicine) documented contamination, incorrect?

Cohen et al. (2022, JAMA Internal Medicine) documented contamination, incorrect concentrations, and mislabeled compounds in unregulated peptide markets, which is the real risk of gray-market sourcing.

What does the video say about anecdotal outcomes from a clinical practice, even at scale, cannot?

Anecdotal outcomes from a clinical practice, even at scale, cannot establish that BPC-157 works better than placebo without a control group. This is how confirmation bias enters clinical decision-making.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Maya Moore, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.